Navigation Links
Bacterin International to Present at Stifel Nicolaus 2012 Healthcare Conference on September 6, 2012
Date:8/31/2012

BELGRADE, Mont., Aug. 31, 2012 /PRNewswire/ -- Bacterin International Holdings, Inc. (NYSE Amex: BONE), a leader in the development of revolutionary bone graft material and antimicrobial coatings for medical applications, will present at the Stifel Nicolaus 2012 Healthcare Conference. The conference will be held at the Four Seasons Hotel in Boston, Massachusetts on September 5-6, 2012.  Bacterin is scheduled to present on Thursday, September 6, 2012 at 9:45 a.m. Eastern time, with one-on-one meetings held throughout the day.

Management will discuss the company's business plan and objectives for the remainder of 2012.  The presentation will be available via webcast at: http://www.veracast.com/webcasts/stifel/healthcare2012/55204615.cfm.

For more information about the conference or to schedule a one-on-one meeting with Bacterin management, contact your Stifel representative.

About Bacterin International Holdings

Bacterin International Holdings, Inc. (NYSE Amex: BONE) develops, manufactures and markets biologics products to domestic and international markets. Bacterin's proprietary methods optimize the growth factors in human allografts to create the ideal stem cell scaffold to promote bone, subchondral repair and dermal growth. These products are used in a variety of applications including enhancing fusion in spine surgery, relief of back pain, promotion of bone growth in foot and ankle surgery, promotion of cranial healing following neurosurgery and subchondral repair in knee and other joint surgeries.

Bacterin's Medical Device division develops, employs, and licenses bioactive coatings for various medical device applications. Bacterin's strategic coating initiatives include antimicrobial coatings designed to inhibit biofilm formation and microbial contamination. For further information, please visit www.bacterin.com.

Important Cautions Regarding Forward-looking Statements

This news release contains certain disclosures that may be deemed forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to significant risks and uncertainties. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as "continue," "efforts," "expects," "anticipates," "intends," "plans," "believes," "estimates," "projects," "forecasts," "strategy," "will," "goal," "target," "prospects," "potential," "optimistic," "confident," "likely," "probable" or similar expressions or the negative thereof. Statements of historical fact also may be deemed to be forward-looking statements. We caution that these statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: the Company's ability to launch beta and full product releases, the Company's ability to obtain FDA concurrence use for anti-microbial coatings in a timely manner; the Company's ability to meet its obligations under existing and anticipated contractual obligations; the Company's ability to develop, market, sell and distribute desirable applications, products and services and to protect its intellectual property; the ability of the Company's sales force to achieve expected results; the ability of the Company's customers to pay and the timeliness of such payments, particularly during recessionary periods; the Company's ability to obtain financing as and when needed; changes in consumer demands and preferences; the Company's ability to attract and retain management and employees with appropriate skills and expertise; the impact of increased taxation, changes in market, legal and regulatory conditions and in the applicable business environment, including actions of competitors; and other factors. Additional risk factors are listed in the Company's Annual Report on Form 10-K under the heading "Risk Factors." The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law.

Hayden IR
James Carbonara, Regional Vice President
646-755-7412
james@haydenir.com

Brett Maas, Managing Partner
646-536-7331
brett@haydenir.com


'/>"/>
SOURCE Bacterin International Holdings, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Bacterin Announces First Quarter 2012 Revenue of $7.8 Million, Up 29% Year-over-Year, on Gross Margins of 76%, and 34% Reduction in Operating Loss
2. Bacterin International Signs Its Third National GPO Contract with Novation
3. Bacterin International Signs Its Fourth National GPO Contract with the Premier healthcare alliance
4. Bacterin International Holdings, Inc. Schedules Second Quarter 2012 Financial Earnings Conference Call
5. Bacterin International Announces Second Quarter and Six Months 2012 Financial Results
6. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
7. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
8. Latest Findings in Breastfeeding Science Presented at Medelas 7th International Breastfeeding and Lactation Symposium
9. SurgLine International, Inc. Launches A Wholly Owned Operating Subsidiary To Pursue Cost Containment Strategies
10. International Drug & Explosives Detection Company IDenta Corp. Releases Information to OTC markets.
11. Chindex International, Inc. to Report First Quarter 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... YORK , May 27, 2016 ... biotechs, drug manufacturers, health insurance companies all falling under ... small healthcare companies. While not often talked about, these ... The United States is by far ... world. Advanced Medical Isotope Corp. (OTC: ADMD), Nutranomics Inc. ...
(Date:5/26/2016)... -- TARE (Transarterial Radio-embolization) Using Yttrium-90 ... Overall Decreased Use of Hospital Resource ... healthcare company, has today announced the publication of ... ISPOR (International Society for Pharmacoeconomics and Outcomes Research), ... yttrium-90 glass microspheres is associated with cost savings ...
(Date:5/25/2016)... , May 25,2016 ... the near-infrared Cellvizio platform for urological and surgical ... OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary confocal ... regulatory milestone in the US with the 12 ... and Drug Administration (FDA). This new FDA clearance ...
Breaking Medicine Technology:
(Date:5/28/2016)... ... 2016 , ... After a year and a half of planning the Multiple Pathways of ... Multiple Pathways of Recovery Conference was held May 2 -4, 2016 at the Mystic ... came together to explore the many pathways individuals use to get into and sustain their ...
(Date:5/27/2016)... Gilsum, New Hampshire (PRWEB) , ... May 27, 2016 , ... ... natural skin care products, announced today that it has been recognized as one of ... men entering parenthood. Badger was named as one of nine small businesses providing progressive ...
(Date:5/27/2016)... , ... May 27, 2016 , ... ... to help educate the many who are unaware of the plight of aphasia. ... will run within the “Stroke Awareness” campaign. , The link between stroke and ...
(Date:5/27/2016)... ... May 27, 2016 , ... With ... pharmaceutical, medical and food industries. Aside from its GMP accreditation, Validation Center is ... of successfully certified products, services and staff. , Validation Center is ISO17025 accredited ...
(Date:5/26/2016)... ... May 26, 2016 , ... Intalere, the healthcare industry ... for its inaugural Member Conference at the Paris Hotel in Las Vegas, Nev., ... health of America’s healthcare providers. , The conference was highlighted by the announcement ...
Breaking Medicine News(10 mins):